tiprankstipranks
Trending News
More News >
Oncolys BioPharma, Inc. (JP:4588)
:4588
Japanese Market
Advertisement

Oncolys BioPharma, Inc. (4588) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Oncolys BioPharma, Inc. has a market cap or net worth of ¥14.76B. The enterprise value is ¥14.09B.
Market Cap¥14.76B
Enterprise Value¥14.09B

Share Statistics

Oncolys BioPharma, Inc. has 24,961,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding24,961,600
Owned by Insiders
Owned by Institutions

Financial Efficiency

Oncolys BioPharma, Inc.’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -54.63%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-54.63%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee784.60K
Profits Per Employee-42.12M
Employee Count40
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio7.98
Price to Fair Value4.11
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.39

Income Statement

In the last 12 months, Oncolys BioPharma, Inc. had revenue of 31.38M and earned -1.68B in profits. Earnings per share was -77.17.
Revenue31.38M
Gross Profit31.38M
Operating Income-1.68B
Pretax Income-1.68B
Net Income-1.68B
EBITDA-1.68B
Earnings Per Share (EPS)-77.17

Cash Flow

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00

Dividends & Yields

Oncolys BioPharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.41
52-Week Price Change3.50%
50-Day Moving Average607.36
200-Day Moving Average612.19
Relative Strength Index (RSI)41.18
Average Volume (3m)434.53K

Important Dates

Oncolys BioPharma, Inc. upcoming earnings date is Aug 8, 2025, TBA (Confirmed).
Last Earnings DateMay 9, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date

Financial Position

Oncolys BioPharma, Inc. as a current ratio of 12.28, with Debt / Equity ratio of 14.88%
Current Ratio12.28
Quick Ratio12.26
Debt to Market Cap0.03
Net Debt to EBITDA1.10
Interest Coverage Ratio-365.76

Taxes

In the past 12 months, Oncolys BioPharma, Inc. has paid 3.76M in taxes.
Income Tax3.76M
Effective Tax Rate>-0.01

Enterprise Valuation

Oncolys BioPharma, Inc. EV to EBITDA ratio is -5.65, with an EV/FCF ratio of -4.68.
EV to Sales301.66
EV to EBITDA-5.65
EV to Free Cash Flow-4.68
EV to Operating Cash Flow-4.69

Balance Sheet

Oncolys BioPharma, Inc. has ¥2.41B in cash and marketable securities with ¥324.64M in debt, giving a net cash position of -¥2.09B billion.
Cash & Marketable Securities¥2.41B
Total Debt¥324.64M
Net Cash-¥2.09B
Net Cash Per Share-¥83.58
Tangible Book Value Per Share¥126.07

Margins

Gross margin is 99.97%, with operating margin of -5357.52%, and net profit margin of -5368.27%.
Gross Margin99.97%
Operating Margin-5357.52%
Pretax Margin-5356.28%
Net Profit Margin-5368.27%
EBITDA Margin-5339.03%
EBIT Margin-5341.63%

Analyst Forecast

The average price target for Oncolys BioPharma, Inc. is ¥584.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target¥584.00
Price Target Upside-1.35% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast11.93%
EPS Growth Forecast15.04%

Scores

Smart ScoreN/A
AI Score48
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis